Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Merck
Moodys
Mallinckrodt
McKesson
Baxter

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,092,525

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 10,092,525 protect, and when does it expire?

Patent 10,092,525 protects EPIDIOLEX and is included in one NDA.

This patent has ten patent family members in nine countries.

Summary for Patent: 10,092,525
Title:Use of cannabinoids in the treatment of epilepsy
Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s): Guy; Geoffrey (London, GB), Wright; Stephen (London, GB), Mead; Alice (Cambridge, GB), Devinsky; Orrin (New York, NY)
Assignee: GW Pharma Limited (Vision Park, Histon, Cambridge, GB)
Application Number:15/449,402
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,092,525

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gw Res Ltd EPIDIOLEX cannabidiol SOLUTION;ORAL 210365-001 Sep 28, 2018 RX Yes Yes   Start Trial   Start Trial USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,092,525

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015332212   Start Trial
Brazil 112017007777   Start Trial
Canada 2963208   Start Trial
European Patent Office 3206716   Start Trial
United Kingdom 201418171   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
Merck
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.